What is the efficacy of the HeartWare Ventricular Assist System in the treatment of dilated cardiomyopathy?

Updated: Mar 02, 2021
  • Author: Vinh Q Nguyen, MD, FACC; Chief Editor: Gyanendra K Sharma, MD, FACC, FASE  more...
  • Print
Answer

The HeartWare Ventricular Assist System is a continuous-flow blood pump. In a study comprising 332 patients with NYHA class IV symptoms with UNOS class 1A or 1B listed for cardiac transplantation, survival was high 91% at 180 days and 84% at 360 days in those who received the HeartWare device. [129, 130]  There was also significant improvement in quality of life. [130]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!